Abstract | BACKGROUND: Various treatments are currently available for melasma. However, results are often disappointing. OBJECTIVE: We sought to assess the efficacy and safety of nonablative 1550-nm fractional laser therapy and compare results with those obtained with triple topical therapy (the gold standard). METHODS: Twenty female patients with moderate to severe melasma and Fitzpatrick skin types II to V were treated either with nonablative fractional laser therapy or triple topical therapy ( hydroquinone 5%, tretinoin 0.05%, and triamcinolone acetonide 0.1% cream) once daily for 8 weeks in a randomized controlled observer-blinded study. Laser treatment was performed every 2 weeks for a total of 4 times. Physician Global Assessment was assessed at 3 weeks, 3 months, and 6 months after the last treatment. RESULTS: Physician Global Assessment improved (P < .001) in both groups at 3 weeks. There was no difference in Physician Global Assessment between the two groups. Mean treatment satisfaction and recommendation were significantly higher in the laser group at 3 weeks (P < .05). However, melasma recurred in 5 patients in both groups after 6 months. Side effects in the laser group were erythema, burning sensation, facial edema, and pain; in the triple group side effects were erythema, burning, and scaling. LIMITATIONS: Limitations were: small number of patients; only one set of laser parameters; and a possible difference in motivation between groups. CONCLUSIONS: Nonablative fractional laser therapy is safe and comparable in efficacy and recurrence rate with triple topical therapy. It may be a useful alternative treatment option for melasma when topical bleaching is ineffective or not tolerated. Different laser settings and long-term maintenance treatment should be tested in future studies.
|
Authors | Marije W Kroon, Bas S Wind, Johan F Beek, J P Wietze van der Veen, Ludmila Nieuweboer-Krobotová, Jan D Bos, Albert Wolkerstorfer |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 64
Issue 3
Pg. 516-23
(Mar 2011)
ISSN: 1097-6787 [Electronic] United States |
PMID | 21255869
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. |
Chemical References |
- Hydroquinones
- Tretinoin
- Triamcinolone Acetonide
- hydroquinone
|
Topics |
- Administration, Topical
- Adult
- Female
- Humans
- Hydroquinones
(therapeutic use)
- Laser Therapy
(adverse effects, methods)
- Melanosis
(drug therapy, therapy)
- Middle Aged
- Pilot Projects
- Recurrence
- Treatment Outcome
- Tretinoin
(therapeutic use)
- Triamcinolone Acetonide
(therapeutic use)
|